Community acquired respiratory virus infections in cancer patients—Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology

Lilienfeld‐Toal, Marie von; Berger, Annemarie; Christopeit, Maximilian; Hentrich, Marcus; Heußel, Claus Peter; Kalkreuth, Jana; Klein, Michael; Kochanek, Matthias; Penack, Olaf; Hauf, Elke; Rieger, Christina; Silling, Gerda; Vehreschild, Maria J. G. T.; Weber, Thomas; Wolf, Hans‐Heinrich; Lehners, Nicola; Schalk, Enrico; Mayer, Karin

doi:10.1016/j.ejca.2016.08.015

Cited by 76 publications

(77 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recommendations for HSCT patients from the Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology recommend IVIG in general and ribavirin in particular for RSV in patients with cancer, largely based on data in HSCT recipients. 65 Guidelines from the United Kingdom recommend inhaled ribavirin and IVIG for allogeneic HSCT recipients with either LRTI or URTI and risk factors for progression to LRTI; they also suggest oral ribavirin if the inhaled form is not available. 66 Outside of guidelines and recommendations, several prospective and retrospective studies have been published on the treatment of RSV in HSCT patients, and, despite the available literature, there is no commonly accepted approach.…”

Section: Treatmentmentioning

confidence: 99%

Respiratory Viral Infections in Solid Organ and Hematopoietic Stem Cell Transplantation

Paulsen

Danziger‐Isakov

2017

Clinics in Chest Medicine

View full text Add to dashboard Cite

Respiratory viruses are common in solid organ and hematopoietic stem cell transplant recipients and a recognized cause of significant morbidity and mortality. Epidemiology, risk factors, and attributable mortality in both populations are reviewed. In addition, virus-specific prevention and treatment options, including emerging investigational therapies, are discussed for respiratory syncytial virus, influenza, adenovirus, parainfluenza, and other respiratory viruses.

show abstract

Section: Treatmentmentioning

confidence: 99%

Respiratory Viral Infections in Solid Organ and Hematopoietic Stem Cell Transplantation

Paulsen

Danziger‐Isakov

2017

Clinics in Chest Medicine

View full text Add to dashboard Cite

show abstract

“…A lack of data precludes recommendations regarding the routine testing of asymptomatic patients for respiratory virus infections. However, active surveillance of patients living with cancer who have signs and symptoms of respiratory viral infection is strongly indicated . Some respiratory viruses, including respiratory syncytial virus, influenza viruses, and human metapneumovirus, are seasonal and occur most commonly in winter; however, perennial infections have been reported with other viruses, such as parainfluenza viruses, adenovirus, rhinovirus, and coronavirus .…”

Section: Preventing Infectionmentioning

confidence: 99%

“…However, active surveillance of patients living with cancer who have signs and symptoms of respiratory viral infection is strongly indicated . Some respiratory viruses, including respiratory syncytial virus, influenza viruses, and human metapneumovirus, are seasonal and occur most commonly in winter; however, perennial infections have been reported with other viruses, such as parainfluenza viruses, adenovirus, rhinovirus, and coronavirus . Patients who have symptoms compatible with respiratory viral infection should be placed on contact precautions while diagnosis is underway …”

Section: Preventing Infectionmentioning

confidence: 99%

Update on infection control practices in cancer hospitals

Ariza-Heredia

Chemaly

2018

CA A Cancer J Clinicians

View full text Add to dashboard Cite

Therapies in oncology have evolved rapidly over the last years. At the same pace, supportive care for patients receiving cancer therapy has also evolved, allowing patients to safely receive the newest advances in treatment in both an inpatient and outpatient basis. The recognition of the role of infection control and prevention (ICP) in the outcomes of patients living with cancer has been such that it is now a requirement for hospitals and involves multidisciplinary groups. Some unique aspects of ICP for patients with cancer that have gained momentum over the past few decades include catheter-related infections, multidrug-resistant organisms, community-acquired viral infections, and the impact of the health care environment on the horizontal transmission of organisms. Furthermore, as the potential for infections to cross international borders has increased, alertness for outbreaks or new infections that occur outside the area have become constant. As the future approaches, ICP in immunocompromised hosts will continue to integrate emerging disciplines, such as antibiotic stewardship and the microbiome, and new techniques for environmental cleaning and for controlling the spread of infections, such as whole-genome sequencing. CA Cancer J Clin 2018;000:000-000. © 2018 American Cancer Society.

show abstract

“…They include viruses such as influenza, rhinovirus, coronavirus, respiratory syncytial virus (RSV) or parainfluenza and usually present with symptoms of upper respiratory tract infections or influenza like syndrome. Although the clinical course of most infections is harmless, in some cases lower respiratory tract infections (LRTI) may occur, which are associated with a high attributable mortality, primarily due to severe bacterial and fungal superinfections [18]. Current data suggest an overall rate of LRTI of around 30% possibly for all CRV [19,20,21,22] with an associated mortality rate of around 25%.…”

Section: Infections With Community-acquired Respiratory Virusesmentioning

confidence: 99%

“…Bacterial or fungal superinfections should be treated promptly and accordingly. Causal therapy includes oseltamivir (influenza), ribavirin (RSV) and cidofovir (adenovirus), whereas effective treatment options for infections by other CRV are not yet available [18]. …”

Section: Infections With Community-acquired Respiratory Virusesmentioning

confidence: 99%

Challenges in Infectious Diseases for Haematologists

Lilienfeld‐Toal

Maschmeyer

2018

Oncol Res Treat

Self Cite

View full text Add to dashboard Cite

Infections remain a threat for patients with haematological malignancies. In accordance with the European Hematology Association roadmap we provide a concise overview regarding the most relevant current challenges in infectious diseases for haematologists. These include bacterial infections and the need for antibiotic stewardship as well as infections with community-acquired respiratory viruses, infections in patients receiving targeted therapies, re-activations of latent infections and vaccination strategies. The following review intends to summarise the most relevant information for clinicians currently caring for patients with haematological malignancies. Recommendations given are based on the guidelines published by the Infectious Diseases Working Party of the German Society of Haematology and Medical Oncology.

show abstract

Community acquired respiratory virus infections in cancer patients—Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology

Abstract: CRV infections may pose a vital threat to patients with underlying malignancy. This guideline provides information on diagnosis and treatment to improve the outcome.

Cited by 76 publications

References 128 publications

Respiratory Viral Infections in Solid Organ and Hematopoietic Stem Cell Transplantation

Respiratory Viral Infections in Solid Organ and Hematopoietic Stem Cell Transplantation

Update on infection control practices in cancer hospitals

Challenges in Infectious Diseases for Haematologists

Contact Info

Product

Resources

About